Page last updated: 2024-10-27

fluoxetine and Aphasia

fluoxetine has been researched along with Aphasia in 1 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Aphasia: A cognitive disorder marked by an impaired ability to comprehend or express language in its written or spoken form. This condition is caused by diseases which affect the language areas of the dominant hemisphere. Clinical features are used to classify the various subtypes of this condition. General categories include receptive, expressive, and mixed forms of aphasia.

Research Excerpts

ExcerptRelevanceReference
"Pharmacotherapy of aphasia had been discussed for the last twenty years with first bromocriptine and amphetamine and then serotoninergic, GABAergic and cholinergic agents."4.84Pharmacotherapy of aphasia: myth or reality? ( de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P, 2007)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
de Boissezon, X1
Peran, P1
de Boysson, C1
Démonet, JF1

Reviews

1 review available for fluoxetine and Aphasia

ArticleYear
Pharmacotherapy of aphasia: myth or reality?
    Brain and language, 2007, Volume: 102, Issue:1

    Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil;

2007